Join CTTC | Print Page | Contact Us | Sign In
CTTC 2020 Webinar - Elizabeth Krakow & Aude Chapuis
Register Tell a Friend About This EventTell a Friend
 

 Export to Your Calendar 8/26/2020
When: August 26, 2020
9:00am PT/12:00pm ET
Where: Canada
Contact: CTTC Head Office
604-874-4944


Online registration is available until: 8/25/2020
« Go to Upcoming Event List  

 

9:00am PT/12:00pm ETCME Credit Hours: 1.0

TCR T Cells, WT-1 T Cells and HA-1 TCR T Cells

Elizabeth KrakowMD & Aude ChapuisMD (Fred Hutchinson Cancer Research Center, Seattle, WA)

Brief Biographies:
Dr. Elizabeth Krakow completed her hematology training at McMaster University and a fellowship in hematopoietic cell transplantation at Hôpital Maisonneuve-Rosemont in Montreal. She is an attending physician at Seattle Cancer Care Alliance and clinical researcher at Fred Hutchinson Cancer Research Center. She takes care of adult BMT patients in all phases of transplantation and post-transplant recovery. She leads translational trials of novel cellular immunotherapies to treat post-transplant leukemia relapse.

Dr. Aude Chapuis is an expert in adoptive T-cell immunotherapies and hematopoietic stem cell transplantation. She received her medical and research training in Switzerland and completed her postdoctoral training and oncology fellowship in Seattle, at the Fred Hutchinson Cancer Research Center and the University of Washington, where she is now a faculty member. 

Dr. Chapuis and her team are expert at identifying and validating optimal high-affinity T cell receptors (TCRs), engineering T cells with specific TCR genes, preparing certified T cell products for clinical trials and assessing their function in patients. Ongoing studies aim to 1) improve the survival and intrinsic antitumor activity of transferred T cells and 2) modulate cells in tumor “microenvironments” to improve therapeutic T cell activity. She has prepared and maintained successful investigator-initiated Investigational New Drug applications for the U.S. F.D.A., and written and served as the Principal Investigator of numerous adoptive immunotherapy trials.

Synopsis:
T cells can be engineered with particular T cell receptor (TCR) molecules that bind pieces of specific proteins (antigens) and thereby direct T cells to attack cells expressing those antigens. In this webinar, researchers from the Fred Hutchinson Cancer Research Center will discuss their recent and ongoing clinical trials of WT-1 and HA-1 specific TCR T cells to prevent and treat post-transplant leukemia relapse. They will review the clinical results and progress of these trials, discuss different approaches to generating antigen-specific T cells including expansion of naturally-occurring T cell clones vs. genetic engineering, elaborate on the factors associated with successful transfer of immune TCR T cells, and describe methods that may improve TCR T cell survival, proliferation and anti-tumor activity of infused T cells. 

Learning Objectives:
1. Describe how TCR T cell differ from CAR-T cells
2. Familiarize participants with strategies for finding TCR targets and high-affinity, highly specific TCRs and for manufacturing TCR T cells
3. Share clinical results of TCR T cell trials to prevent and treatment post-transplant leukemia/MDS relapse

 

*NEW* We have updated our webinar registration process. After completing your registration on our website you will be asked to finalize your registration with GoToWebinar to receive a confirmation email containing all of the information about joining the webinar.

 

This website is sponsored by an 
unrestricted educational grant from: